Journal of Oncology

Immunotherapy: A New Hope for Cancer Patients


Publishing date
01 Oct 2019
Status
Closed
Submission deadline
17 May 2019

Lead Editor

1King George's Medical University, Lucknow, India

2Banaras Hindu University, Varanasi, India

3University of Sheffield, Sheffield, UK

4University of Nebraska Medical Center, Omaha, USA

5CSIR-Indian Institute of Toxicology Research, Lucknow, India

This issue is now closed for submissions.
More articles will be published in the near future.

Immunotherapy: A New Hope for Cancer Patients

This issue is now closed for submissions.
More articles will be published in the near future.

Description

In December 1971, the President of the United States of America established an extended effort to find a cure for cancer. Since then, the cancer research community has built a significant advance in understanding the pathogenesis of the disease. However, cancer remains one of the leading causes of death worldwide. Chemotherapy, radiation, and surgery have been utilized as the primary weapon against cancer. All the same, these treatments have added little to the overall survival of the patients. In addition, these therapies produce numerous side effects and cannot be afforded by a wide range of people.

Cancer immunotherapy was selected as the breakthrough therapy of 2013 in the field of cancer treatment (Jennifer Couzin-Frankel, Science, 342 (2013): 1432-1433; Marcia McNutt, Science 342 (2013): 1417). Immunotherapy aims to target the immune system and not the tumor itself. The immune responses have the potential to increase and sustain over time. It undergoes pseudoprogression which may reflect the development of antitumor immunity. Immunotherapy uses antibodies that bind to and inhibit the function of cancer related proteins in a specific manner. Immunotherapy also includes usage of vaccines and T cell infusions.

Although immunotherapy has provided a new hope, it does not help every cancer patient. Why some patients do not benefit from immunotherapy is the focus of this special issue. We invite the authors to contribute original research articles as well as review articles to this special issue. We are particularly interested in articles that offer an overview of the existing concepts, novel findings, controversies, and challenges in this area. Articles on future prospects of immunotherapy are invited.

Potential topics include but are not limited to the following:

  • Multidrug resistance and cancer immunotherapy
  • Immune system and multiple steps of tumor growth
  • Immunological aspects of epithelial-to-mesenchymal transition
  • Cancer stem cells as target for immunotherapy
  • Role of inflammatory molecules in cancer immunotherapy
  • Role of noncoding RNAs in cancer immunotherapy
  • Immuno-oncology signaling molecules
  • Role of tumor microenvironment in cancer immunotherapy
  • Role of metabolism in cancer immunotherapy
  • Role of human microbiome in cancer immunotherapy
  • Safety and toxicity associated with cancer immunotherapy

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 8970645
  • - Research Article

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers

Alessandra Rossi | Minna Voigtlaender | ... | Mascha Binder
  • Special Issue
  • - Volume 2019
  • - Article ID 1856594
  • - Research Article

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

Umang Swami | Varun Monga | ... | Mohammed Milhem
  • Special Issue
  • - Volume 2019
  • - Article ID 9852361
  • - Research Article

PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts

Ana Carolina Martínez-Torres | Kenny Misael Calvillo-Rodríguez | ... | Cristina Rodríguez-Padilla
  • Special Issue
  • - Volume 2019
  • - Article ID 2563092
  • - Research Article

Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma

Elda-Georgina Chavez-Cortez | Gustavo Vargas Felix | ... | Benjamin Pineda
  • Special Issue
  • - Volume 2019
  • - Article ID 9014607
  • - Review Article

Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art

F. Toia | A. B. Di Stefano | ... | A. Cordova
  • Special Issue
  • - Volume 2019
  • - Article ID 6313242
  • - Review Article

A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

Mohammad A. I. Al-Hatamleh | Suhana Ahmad | ... | Rohimah Mohamud
  • Special Issue
  • - Volume 2019
  • - Article ID 9513701
  • - Review Article

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives

Diego De Goycoechea | Gregoire Stalder | ... | Michel A. Duchosal
  • Special Issue
  • - Volume 2019
  • - Article ID 5269062
  • - Review Article

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors

Anne Rogiers | Annelies Boekhout | ... | Bart Neyns
  • Special Issue
  • - Volume 2019
  • - Article ID 4304817
  • - Review Article

The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors

Malek Kreidieh | Youssef H. Zeidan | Ali Shamseddine
  • Special Issue
  • - Volume 2019
  • - Article ID 2186494
  • - Review Article

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

Rachel E. Cooke | Rachel Koldej | David Ritchie
Journal of Oncology
 Journal metrics
Acceptance rate33%
Submission to final decision92 days
Acceptance to publication49 days
CiteScore3.220
Impact Factor2.600
 Submit